| Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) (NCT05233618) | Karen Ballen, MD | 2022-07-13 |
| A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (NCT05428969) | Faron Pharmaceuticals Ltd | 2022-06-02 |
| Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML (NCT05184842) | Montefiore Medical Center | 2022-03-23 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (NCT05107856) | Prelude Therapeutics | 2022-03-22 |
| Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes (NCT05038592) | M.D. Anderson Cancer Center | 2022-03-04 |
| A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies (NCT04937166) | Kahr Medical | 2022-01-13 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS (NCT04708054) | M.D. Anderson Cancer Center | 2021-10-21 |
| Inqovi Maintenance Therapy in Myeloid Neoplasms (NCT04980404) | Massachusetts General Hospital | 2021-09-17 |
| A Study of E7820 in People With Bone Marrow (Myeloid) Cancers (NCT05024994) | Memorial Sloan Kettering Cancer Center | 2021-08-13 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation (NCT03602898) | Fred Hutchinson Cancer Center | 2021-06-01 |
| Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML (NCT04842604) | Pfizer | 2021-05-17 |
| A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML (NCT04730258) | Treadwell Therapeutics, Inc | 2021-04-16 |
| Methods of T Cell Depletion Trial (MoTD) (NCT04888741) | University of Birmingham | 2021-02-22 |
| Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders (NCT04761770) | Memorial Sloan Kettering Cancer Center | 2021-02-15 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT04655755) | M.D. Anderson Cancer Center | 2021-01-19 |
| NTX-301 in MDS/AML (NCT04167917) | University of Alabama at Birmingham | 2021-01-06 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS (NCT04358393) | Ascentage Pharma Group Inc. | 2020-12-04 |
| A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT04609826) | Janssen Research & Development, LLC | 2020-11-26 |
| Study to Evaluate the Safety and Tolerability of EP0042 (NCT04581512) | Ellipses Pharma | 2020-11-02 |
| IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT (NCT04522895) | Heinrich-Heine University, Duesseldorf | 2020-08-27 |
| A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (NCT04239157) | M.D. Anderson Cancer Center | 2020-08-25 |
| Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911) | Zachariah Michael DeFilipp | 2020-08-14 |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations (NCT04493138) | M.D. Anderson Cancer Center | 2020-07-21 |
| Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant (NCT03964506) | Omar Aljitawi | 2020-07-01 |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) (NCT04256317) | Taiho Oncology, Inc. | 2020-05-21 |
| Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome (NCT04160052) | M.D. Anderson Cancer Center | 2019-10-01 |
| A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) (NCT04093570) | Taiho Oncology, Inc. | 2019-09-30 |
| Combining Active and Passive DNA Hypomethylation (NCT03999723) | Kirsten Grønbæk | 2019-09-11 |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03670966) | Fred Hutchinson Cancer Center | 2019-07-10 |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03850574) | Aptose Biosciences Inc. | 2019-03-11 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT03862157) | M.D. Anderson Cancer Center | 2019-02-27 |
| A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes (NCT03746041) | University of Rochester | 2019-02-14 |
| Effect of Food on Blood Levels of ASTX727 (NCT03813186) | Astex Pharmaceuticals, Inc. | 2018-11-08 |
| Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (NCT03672539) | M.D. Anderson Cancer Center | 2018-11-07 |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation (NCT03734601) | Stanford University | 2018-11-05 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (NCT03289910) | National Cancer Institute (NCI) | 2018-09-24 |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation (NCT03683433) | M.D. Anderson Cancer Center | 2018-09-18 |
| Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine (NCT03588078) | Groupe Francophone des Myelodysplasies | 2018-09-15 |
| IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation (NCT03515512) | Massachusetts General Hospital | 2018-07-17 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT03358719) | Roswell Park Cancer Institute | 2018-03-27 |
| Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (NCT03418038) | Mayo Clinic | 2018-03-23 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921) | Fred Hutchinson Cancer Center | 2018-02-23 |
| Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes (NCT03363399) | University Hospital, Grenoble | 2018-02-22 |
| Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML (NCT03306264) | Astex Pharmaceuticals, Inc. | 2018-02-15 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193) | M.D. Anderson Cancer Center | 2018-01-18 |
| Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome (NCT03383575) | M.D. Anderson Cancer Center | 2018-01-17 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome (NCT03047993) | M.D. Anderson Cancer Center | 2017-11-15 |
| Ascorbic Acid Levels in MDS, AML, and CMML Patients (NCT03526666) | Van Andel Research Institute | 2017-11-01 |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies (NCT03263637) | AstraZeneca | 2017-10-24 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034) | Fred Hutchinson Cancer Center | 2017-10-24 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (NCT03066648) | Novartis Pharmaceuticals | 2017-07-06 |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) (NCT02564536) | Washington University School of Medicine | 2017-06-01 |
| Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms (NCT03072043) | H. Lee Moffitt Cancer Center and Research Institute | 2017-05-18 |
| WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT02666950) | Mayo Clinic | 2017-05-05 |
| Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent (NCT03146871) | University of Southern California | 2017-04-20 |
| Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT (NCT03018223) | H. Lee Moffitt Cancer Center and Research Institute | 2017-01-31 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02960646) | M.D. Anderson Cancer Center | 2017-01-18 |
| Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed (NCT02935361) | University of Southern California | 2016-11-02 |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant (NCT02684162) | M.D. Anderson Cancer Center | 2016-06-22 |
| Personalized NK Cell Therapy in CBT (NCT02727803) | M.D. Anderson Cancer Center | 2016-05-19 |
| Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome (NCT02553941) | Brian Jonas | 2016-05-17 |
| Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) (NCT02268253) | Stemline Therapeutics, Inc. | 2016-02-10 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies (NCT02556931) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-12-01 |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02566304) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-11-13 |
| A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients (NCT02367456) | Pfizer | 2015-04-28 |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (NCT02397720) | M.D. Anderson Cancer Center | 2015-04-07 |
| Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML) (NCT03280888) | Centre Hospitalier Universitaire de Nice | 2014-11-05 |
| Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies (NCT02129101) | Mayo Clinic | 2014-05-01 |
| Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia (NCT01885689) | City of Hope Medical Center | 2014-02-10 |
| Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01894477) | Fred Hutchinson Cancer Center | 2013-11-01 |
| Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (NCT01812252) | Fred Hutchinson Cancer Center | 2013-08-19 |
| Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine (NCT01928537) | Traws Pharma, Inc. | 2013-08-01 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01834248) | Roswell Park Cancer Institute | 2013-07-30 |
| Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms (NCT01908387) | Celgene Corporation | 2013-07-01 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies (NCT01823198) | M.D. Anderson Cancer Center | 2013-06-11 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01664897) | M.D. Anderson Cancer Center | 2013-05-16 |
| Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT01831232) | Fred Hutchinson Cancer Center | 2013-05-01 |
| Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS (NCT02190695) | Fox Chase Cancer Center | 2013-04-01 |
| GVAX vs. Placebo for MDS/AML After Allo HSCT (NCT01773395) | Dana-Farber Cancer Institute | 2013-01-08 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01757639) | National Cancer Institute (NCI) | 2012-12-14 |
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis (NCT01749111) | Hospital Israelita Albert Einstein | 2012-12-01 |
| Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) (NCT01736683) | Merck Sharp & Dohme LLC | 2012-11-28 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia (NCT01772420) | Albert Einstein College of Medicine | 2012-10-01 |
| Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia (NCT01629082) | National Heart, Lung, and Blood Institute (NHLBI) | 2012-06-06 |
| Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia (NCT01620216) | OHSU Knight Cancer Institute | 2012-05-11 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (NCT01558778) | Roswell Park Cancer Institute | 2012-05-01 |
| Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (NCT01522976) | National Cancer Institute (NCI) | 2012-03-01 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS (NCT01300572) | Fred Hutchinson Cancer Center | 2012-01-01 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (NCT01427881) | Fred Hutchinson Cancer Center | 2011-09-01 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies (NCT01384513) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-08-04 |
| Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (NCT01398462) | JW Pharmaceutical | 2011-07-01 |
| 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) (NCT01404741) | Universitätsklinikum Hamburg-Eppendorf | 2011-07-01 |